Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
February 29, 2024CancersOpen Access

Ixazomib, Lenalidomide, and Dexamethasone (IRD) Treatment with Cytogenetic Risk-Based Maintenance in Transplant-Eligible Myeloma: A Phase 2 Multicenter Study by the Nordic Myeloma Study Group

View Full Paper
Ask AI
Bookmark
Share

Authors

APAnu PartanenAWAnders WaageVPValdas Pečeliūnas

Discussion

Loading...

Member takes

Overview

Key Points

Key points are not available for this paper at this time.

Cite This Study

Partanen et al. (2024) studied this question.

synapsesocial.com/papers/68e76e58b6db6435876e3aa8https://doi.org/10.3390/cancers16051024
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Twice‐weekly induction with ixazomib–lenalidomide–dexamethasone (<scp>IRd</scp>) combination followed by extended <scp>IRd</scp> consolidation and lenalidomide maintenance in transplant‐eligible patients with newly diagnosed multiple myeloma: Results of the phase 2 study IFM2014‐032024 · 1 citations
  2. 2Maintenance Strategies in High-Risk Myeloma: A Multicenter Comparison of Bortezomib–Lenalidomide Versus Lenalidomide Alone: A USMIRC Multicenter Analysis2026
  3. 3MRD dynamics during maintenance therapy in 259 patients with nontransplant eligible multiple myeloma2024 · 3 citations
  4. 4Low conversion rates to minimal residual disease (MRD) negativity despite improved IMWG responses with lenalidomide-isatuximab maintenance after autologous stem cell transplant (ASCT) in multiple myeloma.2025
  5. 5Immune-MRD status informs tumor-MRD outcome prognostication in patients with multiple myeloma on lenalidomide maintenance2025 · 3 citations